Methods of using desensitizing drug products

Abstract

Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents.

What is claimed is: 
     
         1 . A method of treating premature ejaculation in a patient, the method comprising:
 administering to the surface of a penis a pharmaceutical composition comprising an anesthetic agent selected from the group consisting of lidocaine, tetracaine, procaine, mepivacaine, bupivacaine, and etidocaine; a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   
       a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol selected from the group consisting of methanol, propanol, isopropyl alcohol, butanol, ethanol, menthol, and eugenol; and a base; 
       and wherein the second melting point depressing agent is different from the first melting point depressing agent, the second melting point depressing agent is 10% by weight based on the total weight of the pharmaceutical composition; and the pharmaceutical composition having a ratio of anesthetic agent to first melting point depressing agent of about 9:1 by weight; and
 relieving symptoms of premature ejaculation. 
 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition does not contain prilocaine. 
     
     
         3 . The method of  claim 2 , wherein the base comprises an aqueous solution, and wherein the aqueous solution comprises a pH in the range of about 6.9 to about 8.9. 
     
     
         4 . The method of  claim 3 , wherein the aqueous solution comprises a pH of about 6.9. 
     
     
         5 . The method of  claim 3 , wherein the aqueous solution comprises a pH of about 7.9. 
     
     
         6 . The method of  claim 3 , wherein the aqueous solution comprises a pH of about 8.9. 
     
     
         7 . The method of  claim 1 , wherein the administering is performed using a metered spray. 
     
     
         8 . The method of  claim 7 , wherein the administering comprises a number of sprays in the range of 3 sprays to 10 sprays. 
     
     
         9 . The method of  claim 1 , wherein the pharmaceutical composition comprises a viscosity sufficient to permit delivery of the pharmaceutical composition through a spray bottle. 
     
     
         10 . The method  claim 1 , wherein the anesthetic agent is lidocaine, the first melting point depressing agent is thymol, and the second melting point depressing agent is ethanol. 
     
     
         11 . The method of  claim 10 , wherein the lidocaine comprises about 8.33% by weight based on the total weight of the pharmaceutical composition, the thymol comprises about 1.0% by weight based on the total weight of the pharmaceutical composition, and the ethanol comprises about 10% by weight based on the total weight of the pharmaceutical composition. 
     
     
         12 . A method of treating premature ejaculation in a patient, the method comprising:
 administering to the surface of a penis a pharmaceutical composition comprising an anesthetic agent selected from the group consisting of lidocaine, tetracaine, procaine, mepivacaine, bupivacaine, and etidocaine; a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   
       a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol selected from the group consisting of methanol, propanol, isopropyl alcohol, butanol, ethanol, menthol, and eugenol; and an aqueous solution; 
       and wherein the second melting point depressing agent is different from the first melting point depressing agent, the second melting point depressing agent is 10% by weight based on the total weight of the pharmaceutical composition; and the pharmaceutical composition having a ratio of anesthetic agent to first melting point depressing agent of about 9:1 by weight; and
 relieving symptoms of premature ejaculation. 
 
     
     
         13 . The method of  claim 12 , wherein the pharmaceutical composition does not contain prilocaine. 
     
     
         14 . The method of  claim 13 , wherein the aqueous solution comprises a pH in the range of about 6.9 to about 8.9. 
     
     
         15 . The method of  claim 14 , wherein the aqueous solution comprises a pH of about 6.9. 
     
     
         16 . The method of  claim 14 , wherein the aqueous solution comprises a pH of about 7.9. 
     
     
         17 . The method of  claim 14 , wherein the aqueous solution comprises a pH of about 8.9. 
     
     
         18 . The method of  claim 12 , wherein the administering is performed using a metered spray. 
     
     
         19 . The method of  claim 12 , wherein the anesthetic agent is lidocaine, the first melting point depressing agent is thymol, and the second melting point depressing agent is ethanol. 
     
     
         20 . The method of  claim 19 , wherein the lidocaine comprises about 8.33% by weight based on the total weight of the pharmaceutical composition, the thymol comprises about 1.0% by weight based on the total weight of the pharmaceutical composition, and the ethanol comprises about 10% by weight based on the total weight of the pharmaceutical composition.